Name | Ribostamycin sulfate |
Description | Ribostamycin sulfate (Vistamycin sulfate) , an aminoglycoside antibiotic, contains a neutral sugar moiety and is produced by Streptomyces ribosome. |
In vitro | Compared to other antibiotics, Ribostamycin (400 mg/kg/day) exhibits the lowest ototoxicity and maintains lower drug concentrations in the inner ear fluid of guinea pigs. Ribostamycin demonstrates minimal ototoxicity to both the cochlea and vestibular apparatus in guinea pigs. |
In vivo | Ribostamycin effectively inhibits aminoglycoside-modifying enzymes in gentamicin-resistant Pseudomonas aeruginosa without suppressing protein disulfide isomerase (PDI) activity, although it does inhibit its chaperone activity. At a 100:1 molar ratio with PDI, Ribostamycin nearly completely inhibits chaperone activity. The dissociation constant (KD) for Ribostamycin binding to immunogenic PDI is 0.319 mM. Additionally, Ribostamycin exhibits antibacterial activity against Borrelia burgdorferi with a minimum inhibitory concentration (MIC) of 18.7 mg/L. At a concentration of 16 mcg/mL, Ribostamycin inhibits P. stagnora, P. zopfii, and P. wickerhamii strains by 100%, 100%, and 95%, respectively. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : Insoluble H2O : 10 mM
|
Keywords | Inhibitor | Vistamycin | inhibit | Ribostamycin sulfate | Antibiotic | Vistamycin Sulfate | Bacterial | Ribostamycin | Ribostamycin Sulfate |
Related Compound Libraries | Bioactive Compound Library | Natural Product Library | Drug Repurposing Compound Library | Saccharide and Glycoside Natural Product Library | Microbial Natural Product Library | Natural Product Library for HTS | Anti-infective Natural Product Library | Bioactive Compounds Library Max |